DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aldurazyme (Laronidase) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

ALDURAZYME SUMMARY

ALDURAZYME® (laronidase) is a polymorphic variant of the human enzyme, (alpha)-L-iduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. (alpha)-L-iduronidase (glycosaminoglycan (alpha)-L-iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal (alpha)-L-iduronic acid residues of dermatan sulfate and heparan sulfate.

ALDURAZYME is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established.

ALDURAZYME has been shown to improve pulmonary function and walking capacity. ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder.


See all Aldurazyme indications & dosage >>

ALDURAZYME NEWS HIGHLIGHTS

Published Studies Related to Aldurazyme (Laronidase)

Laronidase for treating mucopolysaccharidosis type I. [2007.09.30]

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). [2004.05]

Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I. [2008.07]

Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). [2007.07]

A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. [2007.02]

more >>

Clinical Trials Related to Aldurazyme (Laronidase)

A Dose-Optimization Study of AldurazymeŽ (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease [Completed]

Phase 3 Extension Study of the Safety and Efficacy of AldurazymeŽ (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients [Completed]

A Study Evaluating the Safety and Pharmacokinetics of AldurazymeŽ (Laronidase) in MPS I Patients Less Than 5 Years Old [Completed]

Study of AldurazymeŽ Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease [Completed]

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG Levels in AldurazymeŽ Treated Patients [Recruiting]

more >>

Page last updated: 2008-11-02

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008